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 OBJECTIVES:  The occurrence of decompensation marks a crucial turning point in the course of cirrhosis. The 
purpose of this study was to assess the risk of mortality according to the clinical characteristics 
of fi rst decompensation, considering also the impact of acute-on-chronic liver failure (AoCLF). 
 METHODS:  We conducted a prospective nationwide inception cohort study in Italy. Decompensation 
was defi ned by the presence of ascites, either overt or detected by ultrasonography (UD), 
gastroesophageal variceal bleeding (GEVB), and hepatic encephalopathy (HE). AoCLF was 
defi ned according to the Asian Pacifi c Association for the Study of the Liver criteria. Multivariable 
Cox proportional hazards regression was used to analyze the risk of failure (death or orthotopic 
liver transplantation (OLT)). 
 RESULTS:  A total of 490 consecutive cirrhotic patients (314 males, mean age 60.9 ± 12.6 years) fulfi lled the 
study criteria. AoCLF was identifi ed in 59 patients (12.0 % ). Among the remaining 431 patients, 
ascites were found in 330 patients (76.6 % ): in 257 (77.8 % ) as overt ascites and in 73 (22.2 % ) 
as UD ascites. GEVB was observed in 77 patients (17.9 % ) and HE in 30 patients (7.0 % ). After 
a median follow-up of 33 months, 24 patients underwent OLT and 125 died. The cumulative 
incidence of failure (death or OLT) after 1, 2, and 3 years was, respectively, 28, 53, and 62 % in 
patients with AoCLF; 10, 18, and 25 % in patients with UD ascites; 17, 31, and 41 % in patients 
with overt ascites; and 8, 12, and 24 % in patients with GEVB ( P  <  0.0001). 
 CONCLUSIONS:  AoCLF is responsible for a relevant proportion of fi rst decompensation in cirrhotic patients and is 
associated with the poorest outcome. Patients with UD ascites do not have a negligible mortality 
rate and require clinical monitoring similar to that of patients with overt ascites . 
 SUPPLEMENTARY MATERIAL is linked to the online version of the paper at  http://www.nature.com/ajg 
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 INTRODUCTION 
 Th e disease course of cirrhosis, one of the worldwide leading 
causes of death, is characterized by an initial symptomless period 
of variable extent ( 1 ). However, during this chronic process, 
increasing portal pressure and decreasing liver function over time 
result in the development of hepatic decompensation that corre-
sponds to a crucial turning point of this condition because it is 
associated with over 50 % risk of further complications or death 
within a relatively short period of time ( 2 – 4 ). Th is decompensated 
stage deeply aff ects both the clinical management and the follow-
up strategies ( 5 – 7 ). Despite the magnitude of the problem, a sur-
vey that assessed the outcome of patients with cirrhosis since the 
onset of decompensation according to its clinical features, namely 
inception cohort study, is still lacking. 
 In the attempt to overcome the weaknesses of the available infor-
mation, D ’Amico  et al. ( 8 ) carried out a systematic review. Based 
on its results, they proposed to categorize cirrhotic patients by a 
multiple-step classifi cation that identifi es two stages of decompen-
sated cirrhosis according to the characteristics of complications at 
presentation, and to their diff erent rates of mortality. Neverthe-
less, the quoted systematic review suff ers from several important 
methodological fl aws as a consequence of being modeled by data 
collected retrospectively and obtained from studies carried out in 
a period when treatment of portal hypertension-related compli-
cations was still in its infancy. Furthermore, the suggested stage 
system ( 8 ) did not distinguish patients at their fi rst decompensa-
tion from those who had already experienced it. Moreover, the 
authors did not consider the clinical impact of the acute deteriora-
tion upon a preexisting liver disease (acute-on-chronic liver failure 
(AoCLF)), the defi nition of which was only recently stated by the 
Asian Pacifi c Association for the Study of the Liver (APASL) ( 9 ). 
Finally, one more interesting issue on this topic, which has never 
been investigated so far, refers to the prognostic importance and 
the clinical outcome of ascites detectable only by ultrasonography 
since its fi rst occurrence. 
 Th e aim of this prospective nationwide inception cohort study 
(EPA-SCO) was to evaluate the disease course of cirrhosis since 
the onset time of the fi rst complication. Th e enrolled patients were 
allocated in distinct subcohorts according to the diff erent charac-
teristic of decompensation at study entry. 
 METHODS 
 Th e EPA-SCO study was carried out on behalf of the Italian 
Association for the Study of the Liver Disease (AISF). 
 Study population 
 Between October 2007 and October 2008, we enrolled all con-
secutive patients with cirrhosis (either followed by periodically 
surveillance as outpatients or aft er in-hospital admission) in 
whom a fi rst episode of liver decompensation defi ned as (i) ascites 
(overt or ultrasound detected alone (UD), (ii) gastroesophageal 
variceal bleeding (GEVB), (iii) hepatic encephalopathy (HE), 
(iv) jaundice, and (v) hepatorenal syndrome (HRS), has occurred. 
A total of 29 centers scattered throughout Italy agreed to participate. 
Th e collection of personal data was made in full compliance with 
the Italian law on personal data protection, and each patient gave 
his / her consensus in participating. Inclusion criteria were age >18 
years and diagnosis of cirrhosis, whereas all patients with previ-
ous episodes of liver decompensation, diagnosis of hepatocellular 
carcinoma (HCC), HIV co-infection, drug addiction, concomi-
tant extrahepatic neoplasm, hemodialysis, and solid organ or 
bone marrow transplantation were excluded. 
 Diagnostic criteria for inclusion 
 At baseline, demographic, etiologic, and biochemical vari-
ables were set up. Diagnosis of previous compensated cirrhosis 
(either by histology or based on clinical ground) was available in 
all patients who had undergone periodical follow-up. For those 
who were unaware of a preexisting liver disease, diagnosis was 
obtained by the evaluation of clinical certifi cation / record (when 
available) and / or confi rmed during hospitalization by ultrasound, 
computed tomography scan, and upper endoscopy. In the latter 
group of patients, a detailed history of the prior clinical course of 
their disease was accurately investigated at study entry in order to 
confi rm the inclusion criteria. 
 As mentioned above, ascites was diagnosed both by clinical 
examination (overt ascites) and ultrasonography (UD ascites). Th e 
detection of UD ascites was systematically looked for and reported, 
if present, at study entry, and its presence has been confi rmed by 
two independent physicians. UD ascites was ascertained prospec-
tively in patients previously free of ascites who were on regular 
surveillance for their liver condition. For the remaining individ-
uals we cannot exclude that UD ascites could have been already 
present. Diagnostic paracentesis was performed in all patients with 
overt ascites in order to establish its portal-hypertensive nature by 
serum-ascites albumin gradient and to assess the concomitant 
presence of spontaneous bacterial peritonitis (SBP) by a polymor-
phonuclear cell count in ascitic fl uid >250  cell / mm 3 ( 10 ). HRS and 
refractory ascites were diagnosed according to the International 
Ascites Club criteria ( 11 ). Bleeding was attributed to the rupture of 
GEVB by endoscopic report according to Baveno guidelines ( 12 ). 
HE was defi ned as an episode of neurological and neuropsychiatric 
abnormality (drowsiness, mental confusion, and disorientation) 
revertible aft er an eff ective ammonia-lowering treatment ( 13 ). 
Initially, patients were allocated in the above-mentioned subcohort 
categories. Patients with mixed synchronous complications at pres-
entation (i.e., ascites  +  GEVB and ascites  +  HE) were categorized 
apart. Later, in the beginning of 2010, based on the availability 
of the AoCLF criteria developed by the consensus recommenda-
tions of APASL ( 14 ), which includes (i) jaundice (serum bilirubin 
 ≥ 5  mg / dl), (ii) coagulopathy (international normalized ratio  ≥ 1.5), 
and (iii)  de novo occurrence of ascites and / or encephalopathy, the 
protocol was amended. Both the preexisting diagnosis of stable 
compensated cirrhosis and a possible / probable acute hepatic insult 
within a 4-week period before the onset of the above-mentioned 
concurrent conditions were carefully required to certify this diag-
nosis. A detailed report for intake of diff erent drugs or infections 
over the past 3 months was also taken. Accordingly, all patients 
who fulfi lled the APASL criteria at the time of study entry were 
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retrospectively  post hoc allocated in this category. Hence, in order 
to follow the results more easily, patients were presented as AoCLF 
and non-AoCLF subcohorts. 
 Presence of HCC was assessed by two coincidental imaging 
techniques ( 15 ) and, in controversial cases, also by a fi ne needle 
biopsy. 
 Th e etiology of cirrhosis was based on viral markers (anti-HCV 
and hepatitis B surface antigen (HBsAg)), amount and duration 
of alcohol intake, confi rmed by relatives, autoantibodies, markers 
of iron overload, and criteria of metabolic syndrome for nonal-
coholic steatohepatitis (NASH). Cryptogenic cirrhosis was diag-
nosed in the absence of any viral, autoimmune, or metabolic 
etiology. Th e Child – Turcotte – Pugh (CTP) classifi cation ( 16 ), the 
Model for End-Stage Liver Disease (MELD) ( 17 ), and the MELD-
Na ( 18 ) scores were determined at the initial visit. Treatments of 
complications were carried out according to current guidelines in 
all centers ( 10 – 12 ). For patients with UD ascites, a low-salt diet 
was prescribed, and spironolactone was also administered on the 
basis of the Na   +   / K   +   urinary excretion ratio . Patients with GEVB 
received injection sclerotherapy, endoscopic band ligation, or 
transjugular intrahepatic portosystemic shunt. All these patients 
were discharged with  β -blocker secondary prophylaxis unless 
contraindications or subjective intolerance were present. 
 Schedule of follow-up 
 Th e follow-up schedules aft er hospital release were pre-established 
by the writing committee and they were based on 3-month inter-
vals (clinical and biochemical ultrasonography). Th ese schedules 
were not modifi ed aft er the protocol amendment. However, each 
center could adapt the visit periodicity individually, as clinically 
required. 
 Statistical analysis 
 Data were collected in a pre-established electronic CRF database 
(web-based data collection, e-CRF provided by Air-Tel, Airon 
Telematica, Milan, Italy). Diff erences in the distribution of subject 
characteristics between groups were evaluated by the analysis of 
variance and the  χ 2 analysis for continuous and categorical vari-
ables, respectively. In time-to-event analyses, the considered event 
of interest was death or orthotopic liver transplantation (OLT). 
HCC was considered as a competing event. Th e observation 
started from the time of fi rst episode of decompensation. Data 
were censored on the date of the last follow-up visit. Th e cumula-
tive incidences of death or OLT and HCC were calculated using 
the method of Kalbfl eisch and Prentice ( 19 ) and compared across 
diff erent subgroups using the Gray test ( 20 ). For multivariate 
analyses, Cox proportional hazard regression modeling was used 
to analyze the factors associated with the outcomes and hazard 
ratios and 95 % confi dence intervals (CIs) were calculated for the 
strength of association. 
 A direct comparison of a model that includes only MELD score 
as a covariate and a model including also the type of decompen-
sation at baseline was carried out. To evaluate the incremental 
predictive information of the new disease defi nition, we used the 
likelihood ratio test ( 21 ). We also assessed the improvement in risk 
prediction when the covariates age, sex, body mass index, alanine 
transaminase, hemoglobin, sodium, and presence of diabetes were 
incorporated into the model. 
 A  P value of   <  0.05 was considered statistically signifi cant. All 
 P values were two tailed. Statistical analyses were performed 
with the SAS soft ware (version 9.3, Cary, NC), and the R soft ware 
http://www.R-project.org/ . 
 RESULTS 
 A total of 569 subjects were enrolled, and 79 were excluded, either 
because of diagnosis of concurrent HCC or because previously 
reported episodes of decompensation were found. Th e fl owchart 
of the study is illustrated in  Figure 1 . 
 Th e clinical and laboratory characteristics of the 490 evalu-
ated patients at inclusion are shown in  Table 1 . Approximately 
two-thirds of patients were men and the mean age was 60.9 years 
(range: 18 – 87 years). Th e mean values of biochemical param-
eters were consistent with the diagnosis of established cirrhosis. 
Th e distribution of CTP classes was: 19.4 % class A, 61.0 % class B, 
and 19.6 % class C. Gastroesophageal varices were present in 218 
patients (55 small, 79 medium, and 84 large varices) and, among 
them, 91 subjects (41.7 % ) took  β -blockers (propranolol or nad-
olol) as a primary prophylaxis of variceal bleeding. Th e most 
frequent etiological factor was hepatitis C virus (HCV) infection 
(41.0 % ), followed by alcohol abuse (30.0 % ). Th e coexistence of 
HCV and alcohol abuse was ascertained in 11.4 % of patients. Out 
of 244 HCV-positive patients, 82 (33.6 % ) have been previously 
unsuccessfully treated with  α -interferon with or without ribavirin, 
whereas none of them received antiviral therapy during the study 
period. Of the patients, 11 % had hepatitis B virus (HBV) – related 
cirrhosis. Out of 50 HBsAg-positive patients, 10 (20.0 % ) were tak-
ing a nucleoside analog therapy at the time of the enrollment into 
the study. Autoimmunity, iron overload, NASH, and cryptogenic 
569 Recruited patients
79 Excluded patients
(diagnosis of HCC or previous
decompensation)
490 Enrolled patients
35 Patients unwilling
to adhere to protocol
455 Patients for survival
analysis
65 Patients lost to follow-up
125 Deaths
24 OLT 189 Alive 52 HCC
 Figure 1 .  Flowchart of the study. HCC, hepatocellular carcinoma; 
OLT, orthotopic liver transplantation. 
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etiologies accounted for the remaining 17.6 % of cases. Before study 
entry, 178 (36.3 % ) patients had undergone regular surveillance by 
their referral centers. 
 AoCLF subcohort at presentation 
 In all, 59 (12.1 % ) patients fulfi lled the criteria of AoCLF diagnosis. 
 Table 1 (middle column) shows their clinical and laboratory 
 Table 1 .  Baseline characteristics of patients at fi rst episode of decompensation at study entry and according to the presence or absence of AoCLF 
 Variable a  All patients ( n =490)  AoCLF ( n =59) 
 Non-AoCLF (decompen-
sated cirrhosis) ( n =431)  P value 
 Age (years)  60.9 ± 12.6  55.1 ± 13.7  61.7 ± 12.3   <  0.001 
 Gender 
  Male  314 (64.1 % )  42 (71.2 % )  272 (63.1 % )  0.2 
  Female  176 (35.9 % )  17 (28.8 % )  159 (36.9 % )  
 BMI  26.2 ± 4.1  25.7 ± 3.8  26.3 ± 4.1  0.3 
 Serum bilirubin (mg / dl)  3.4 ± 4.0  9.2 ± 6.2  2.6 ± 2.8   <  0.001 
 Serum albumin (g / l)  31.7 ± 6.0  28.7 ± 5.1  32.7 ± 6.1   <  0.001 
 Prothrombin time (INR)  1.40 ± 0.36  1.74 ± 0.24  1.36 ± 0.35   <  0.001 
 ALT (u.l.n.)  2.2 ± 1.3  2.1 ± 1.3  2.2 ± 1.3  0.5 
 Hb (g / dl)  11.7 ± 2.2  11.2 ± 2.1  11.8 ± 2.3  0.07 
 Platelets ( × 10 9 / l)  108.6 ± 70.2  119.3 ± 90.2  107.1 ± 67.0  0.2 
 Creatinine (mg / dl)  0.92 ± 0.45  0.90 ± 0.53  0.93 ± 0.44  0.6 
 Sodium (mEq / l)  137.0 ± 4.6  134.8 ± 4.8  137.3 ± 4.5   <  0.001 
 Child – Turcotte – Pugh class 
  A5 / A6  95 (19.4 % )  0  95 (22.0 % )   <  0.001 
  B7 / B9  302 (61.6 % )  22 (37.3 % )  280 (65.0 % )  
  C10 / C15  93 (19.0 % )  37 (62.7 % )  56 (13.0 % )  
 MELD score (median, IQR)  13 (10 – 17)  20 (19 – 23)  13 (10 – 14)   <  0.001 
 MELD-Na (median, IQR)  14 (10 – 19)  23 (19 – 28)  13 (10 – 17)   <  0.001 
 Gastroesophageal varices  218 (44.5 % )  21 (35.6 % )  197 (44.7 % )  0.2 
  Small  55 (25.3 % )  6 (28.6 % )  49 (24.9 % )  0.9 
  Medium  79 (36.2 % )  7 (33.3 % )  72 (36.5 % )  
  Large  84 (38.5 % )  8 (38.1 % )  76 (38.6 % )  
 Etiology 
  HBV  35 b (7.1 % )  1 (1.7 % )  34 (7.9 % )   <  0.001 
  HCV  201 c (41.0 % )  11 (18.6 % )  190 (44.1 % )  
  Alcohol  147 (30.0 % )  35 (59.3 % )  112 (26.0 % )  
  Alcohol / virus  56 (11.4 % )  5 (8.5 % )  51 (11.8 % )  
  Autoimmune (PBC, PSC, AIH)  14 d (2.9 % )  3 (5.1 % )  11 (2.6 % )  
  NASH / cryptogenic  37 (7.6 % )  4 (6.8 % )  33 (7.7 % )  
 In-hospital admission  423 (86.3 % )  58 (98.3 % )  375 (84.7 % )  0.002 
 Outpatients  67 (16.7 % )  1 (1.7 % )  66 (15.3 % )  
 Regular follow-up before the study entry  178 (36.3 % )  19 (32.2 % )  159 (36.9 % )  0.4 
 AIH, autoimmune hepatitis; ALT, alanine transaminase; AoCLF, acute-on-chronic liver failure; BMI, body mass index; Hb, hemoglobin; HBV, hepatitis B virus; HCV, 
hepatitis C virus; HDV, hepatitis D Virus; INR, international normalized ratio; IQR, interquartile range; MELD, Model for End-Stage Liver Disease; MELD-Na, MELD-serum 
sodium; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; u.l.n., upper limit of normal. 
 a Values are number and percentage, mean  ± s.d. or median and IQR. 
 b Including 7 patients with HDV coinfection . 
 c Including 5 hepatitis B surface antigen (HBsAg) – positive patients. 
 d Including one anti-HCV positive patient. 
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was used. Th ree patients had insertion of transjugular intrahepatic 
portosystemic shunt because of the failure of a stable control of 
the bleeding. 
 UD ascites was identifi ed in 73 cases (17.7 % ;  Table 2 ). Among 
them, only 10 patients (13.4 % ) were found to have gastroesopha-
geal varices. Female gender was much more prevalent in compari-
son with the previous two subgroups. 
 Among the remaining 35 patients, mild-to-moderate HE 
was diagnosed in 20 cases ( Table 2 ). Eight patients had acute 
cholangitis and isolated portal vein thrombosis was found in 
7 subjects. 
 Overall, the in-hospital mortality rate of this subcohort of 
patients was 1.2 % . 
 Follow-up and survival analysis 
 Th e median follow-up observed in 455 of 490 (92.9 % ) patients 
(AoCLF and non-AoCLF pooled together) who agreed to be regu-
larly followed aft er hospital discharge was of 33 months (range 
1 – 48), for a total of 872 person-years of observation. No signifi cant 
diff erence of baseline characteristics was found between patients 
who adhered or refused to be followed-up (data not shown). 
During the time of observation, 125 patients died, 24 received 
OLT, and 52 developed HCC (overall incidence 23.0 per 100 per-
son-years, HCC incidence 5.96 per 100 person-years). Sixty-fi ve 
patients lost to follow-up were also included in the survival analy-
sis. For these patients, follow-up was censored at the time of last 
observation (median follow-up of 12.3 months, range 1 – 29) and 
their clinical features (age, sex, etiology, and type of fi rst decom-
pensation) did not diff er from those patients who were still on 
follow-up at the end of the study. 
 Transition to  de novo complications by type of hepatic decom-
pensation at presentation in non-AoCLF patients is reported in 
 Supplementary Material online. 
 Th e cumulative incidence of failure (death or OLT) aft er the fi rst 
episode of decompensation was 16 % (95 % CI: 13 – 20 % ) at 1 year, 
28 % (95 % CI: 24 – 32 % ) at 2 years, and 37 % (95 % CI: 32 – 42 % ) at 
3 years. Th e 3-year cumulative incidence of HCC was 13 % (95 % 
CI: 10 – 17 % ;  Figure 2 ). Th e 3-year cumulative incidence of fail-
ure was 62 % (95 % CI 45 – 75 % ) in AoCLF cohort and 34 % (95 % 
CI 28 – 39 % ) in the non-AoCLF cohorts. Th e main causes of death 
for 125 patients were the following: liver failure ( n  =  77), GEVB 
( n  =  19), sepsis ( n  =  12), HRS ( n  =  8), and other causes unrelated to 
liver disease ( n  =  9;  Table 3 ). 
 Figure 3 shows the curves of cumulative incidence of 
death / OLT according to the above-mentioned criteria. A sig-
nifi cant diff erence of survival across the diff erent subgroups was 
observed (Gray test,  P  <  0.0001).  Table 3 shows the cumulative 
incidence of failure (death and OLT) by type of decompensation 
at baseline. 
 Among 225 HCV patients with available information, 81 (36.0 % ) 
have been previously treated with antiviral therapy. Th e two survival 
curves of treated and untreated subjects were equivalent ( P  =  0.9 by 
log-rank test; data not shown). As for HBV, the number of patients 
was too low to be reliable. During follow-up, 41 patients continued 
to be alcohol abusing. Th eir overall survival rate was lower but not 
features at study entry. At time 0, 46 patients had ascites alone, 
whereas HE was found in 13 patients. In six cases, the combina-
tion of ascites and HE was found. More than two-thirds of patients 
reported alcohol abuse as main determinant of their liver disease. 
Precipitating events of AoCLF were: (i) active alcoholism in 40 
(5 with coexisting infections from urinary tract, two from lung, 
10 without clear acute insult); (ii) drug-induced liver damage 
in 10 (nonsteroidal anti-infl ammatory drugs in 4, amoxicillin –
 clavulanate in 4, hypericum perforatum and other unidentifi ed 
herbal drugs in 2); (iii) active bleeding in 4 cases; and (iv) bacterial 
infections alone in 4 patients. Hepatitis reactivation was found to 
be the precipitating factor in one case due to HBV. Four patients 
had renal failure (creatinine   >  1.5  mg / dl). No patient underwent 
mechanical ventilation or renal replacement. A severe hepatic 
impairment was very frequent: 62.7 % of these subjects belonged 
to CTP class C and overall median value of MELD was 20. In hos-
pital, the mortality rate was 3.4 % . 
 Non-AoCLF subcohort at presentation 
 In  Table 1 , the right column shows the principal clinical and 
laboratory features of 431 patients with non-AoCLF decom-
pensated cirrhosis. In comparison with previous subjects, 
these patients were signifi cantly older, with less severe liver 
impairment. Viral infection predominates as etiological factor 
for cirrhosis. 
 Th e main features of this population according to the etiology 
of their liver disease are shown in  Supplementary Table S1 
online. Patients with HCV-related cirrhosis were the oldest, 
whereas patients with dual etiology (virus plus alcohol) were 
the youngest. Patients with HBV infection or alcohol abuse were 
predominantly men, whereas female gender was highly repre-
sented in autoimmune and NASH / cryptogenic diseases. Compared 
with patients with HCV etiology, subjects with alcohol-related 
disease showed a more advanced stage of their condition (CTP 
class C: 19.6 % vs. 11.1 % ,  P  <  0.001; median MELD: 14 vs. 12, 
 P  <  0.001). As expected, diabetes was present across all groups of 
patients, with the highest prevalence in the NASH / cryptogenic 
group (42.4 % ). 
 Table 2 shows the clinical and laboratory features of 416 non-
AoCLF patients according to the type of clinical complication at 
presentation. In this group of patients, overt ascites was the most 
common cause of decompensation (246 cases, 59.1 % ). Among 
them, 8 patients had concomitant mild or moderate HE. In addi-
tion, 37 patients (15.0 % ) had leg edema. Sixteen patients (6.5 % ) had 
SBP 8 (13 of them were discharged from the hospital aft er starting 
an antibiotic prophylaxis). HRS was diagnosed in only one patient. 
Gastroesophageal varices were discovered in 77 patients (31.3 % ) 
with overt ascites. Interestingly, no diff erence in the occurrence of 
ascites was seen between patients who were receiving or not pro-
phylactic  β -blocker treatment for variceal bleeding (77.4 % vs. 81.1, 
 P  =  0.5). GEVB alone was observed in 66 (15.9 % ) patients, but in 
only 1 patient with concomitant moderate HE. GEVB and overt 
ascites were concomitantly present in 11 patients (3.1 % ;  Table 2 ). 
At hospital admission, 43 patients received sclerotherapy and 30 
endoscopic band ligation, whereas in 7 cases vasoactive therapy 
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statistically signifi cant ( P  =  0.075 by log-rank test; data not shown) 
in comparison with that of abstinent individuals. 
 Predictive model for death / OLT 
 Th e likelihood of the Cox model including only MELD score 
was   −  773 ( Table 4 , model 1). Th e hazard ratio associated 
with a 5-point increase estimated from model 1 was 1.52 (95 % 
CI 1.31 – 1.76). When the type of decompensation (categorized 
as AoCLF, overt ascites, GEVB, and UD) was added to model 1, 
the likelihood increased signifi cantly to   −  769 ( Table 4 , model 2; 
likelihood ratio test  P value  =  0.021). In model 2, the type of 
decompensation remained a statistically signifi cant prognos-
tic factor aft er adjusting for MELD score: when compared with 
GEVB patients, the hazard ratio for AoCLF, overt ascites, and UD 
patients were, respectively, 2.35 (95 % CI: 1.11 – 4.99), 2.05 (95 % 
CI: 1.11 – 3.77), and 1.28 (95 % CI: 0.61 – 2.68). 
 Furthermore, when age, sex, body mass index, alanine transami-
nase, hemoglobin, sodium, and presence of diabetes were added to 
the model, the likelihood increased signifi cantly to   −  734 ( Table 4 , 
model 3; likelihood ratio test  P value   <  0.0001). In addition, from 
 Table 2 .  Baseline clinical and laboratory characteristics of 431 patients with non-AoCLF decompensated cirrhosis according to the 
features of fi rst decompensation 
 Variable a 
 Overt ascites 
( n =246)  GEVB ( n =66) 
 UD ascites 
( n =73)  Other b  ( n =35) 
 GEVB and 
ascites ( n =11)  P value 
 Age (years) range  62.0 ± 12.3  57.4 ± 13.3  63.1 ± 10.5  65.5 ± 12.6  58.7 ± 10.6  0.011 
 Gender 
  Male  165 (67.1 % )  42 (63.6 % )  34 (46.6 % )  22 (62.9 % )  9 (81.8 % )  0.018 
  Female  81 (32.9 % )  24 (36.4 % )  39 (53.4 % )  13 (37.1 % )  2 (18.2 % )  
 BMI  26.5 ± 4.5  25.8 ± 3.1  25.9 ± 3.9  26.4 ± 3.5  27.9 ± 3.5  0.4 
 Serum bilirubin (mg / dl)  2.9 ± 3.0  2.0 ± 1.6  1.4 ± 0.9  4.1 ± 4.9  2.3 ± 1.2   <  0.001 
 Serum albumin (g / l)  30.9 ± 5.9  31.9 ± 5.4  35.1 ± 5.7  35.1 ± 7.0  29.2 ± 4.8   <  0.001 
 Prothrombin time (INR)  1.37 ± 0.32  1.32 ± 0.21  1.34 ± 0.55  1.30 ± 0.27  1.59 ± 0.31  0.13 
 ALT (u.l.n.)  2.2 ± 1.3  2.2 ± 1.3  2.6 ± 1.4  2.2 ± 1.4  2.0 ± 1.3  0.05 
 Hb (g / dl)  12.1 ± 2.0  9.4 ± 2.3  12.7 ± 1.7  13.0 ± 1.8  9.6 ± 1.4   <  0.001 
 Platelets ( × 10 9 / l)  119.5 ± 77.8  79.3 ± 34.1  91.8 ± 47.1  104.7 ± 50.3  106.3 ± 40.4   <  0.001 
 Creatinine (mg / dl)  0.97 ± 0.55  0.84 ± 0.26  0.84 ± 0.24  0.91 ± 0.18  1.0 ± 0.35  0.075 
 Sodium (mEq / l)  136.4 ± 4.8  138.6 ± 3.0  138.7 ± 3.3  138.8 ± 3.7  136.3 ± 6.0   <  0.001 
 Child – Turcotte – Pugh class 
  A5 / A6  22 (8.9 % )  29 (43.9 % )  30 (41.1 % )  13 (37.1 % )  1 (9.1 % )   <  0.001 
  B7 / B9  180 (73.2 % )  33 (50.0 % )  43 (58.9 % )  18 (51.4 % )  6 (54.5 % )  
  C10 / C15  44 (17.9 % )  4 (6.1 % )  0  4 (11.4 % )  4 (36.4 % )  
 MELD score (median, IQR)  13 (11 – 16)  11 (10 – 14)  10 (8 – 12)  13 (9 – 17)  16 (11 – 19)   <  0.001 
 MELD-Na (median, IQR)  14 (11 – 18)  11.5 (10 – 14)  10 (8 – 12.5)  13 (10 – 19)  18 (11 – 27)   <  0.001 
 Etiology 
  HBV  18 (7.3 % )  6 (9.1 % )  6 (8.2 % )  4 (11.4 % )  0  0.03 
  HCV  106 (43.1 % )  21 (31.8 % )  45 (61.6 % )  17 (48.6 % )  1 (9.1 % )  
  Alcohol  76 (30.9 % )  15 (22.7 % )  9 (12.3 % )  5 (14.3 % )  7 (63.6 % )  
  Alcohol / virus  26 (10.6 % )  11 (16.7 % )  7 (9.6 % )  5 (14.3 % )  2 (18.2 % )  
  Autoimmune  4 (1.6 % )  4 (6.1 % )  3 (4.1 % )  0  0  
  NASH / cryptogenic  16 (6.5 % )  9 (13.6 % )  3 (4.1 % )  4 (11.4 % )  1 (9.1 % )  
 Regular follow-up before the study entry  80 (32.5 % )  21 (31.8 % )  40 (54.8 % )  17 (48.6 % )  1 (9.1 % )  0.003 
 ALT, alanine transaminase; AoCLF, acute-on-chronic liver failure; BMI, body mass index; GEVB, gastroesophageal variceal bleeding; Hb, hemoglobin; HBV, hepatitis B 
virus; HCV, hepatitis C virus; INR, international normalized ratio; IQR, interquartile range; MELD, Model for End-Stage Liver Disease; MELD-Na, MELD-serum sodium; 
NASH, nonalcoholic steatohepatitis; UD, ultrasonography detected; u.l.n., upper limit of normal. 
 a Values are number and percentage or mean  ± s.d. 
 b Hepatic encephalopathy, portal vein thrombosis, and cholangitis. 
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generalization of our results, it provides original information 
about the occurrence of AoCLF and subclinical (or UD detected) 
ascites, two interesting clinical entities for which available data 
are scarce. 
 First of all, we wish to emphasize some methodological aspects 
of our survey. Th e prospective enrollment of consecutive patients 
starting from their fi rst complication has reduced potential selec-
tion bias. Moreover, the participation of both tertiary and periph-
eral centers have also minimized referral and recruitment biases 
because of local issues, and the participation of hospitals scattered 
all over the Country provided a representative picture of patients 
with cirrhosis in Italy. 
 At present, HCV is the main etiological cause of cirrhosis 
in patients. Th is does not surprise, considering both the high 
prevalence of this infection in Italy ( 22 ) and the unsatisfactory 
rates of response achieved with current interferon-based treat-
ment regimen. In contrast, the number of patients with HBV 
infection was much lower, confi rming that this condition has 
decreased over the past 20 years in our country, mainly because 
of the national vaccination plan and effi  cacy of antiviral therapy. 
Patients with alcohol-related etiology showed a more severe 
condition of the disease at presentation, irrespective of their 
younger age. 
 Th e observed fi ndings are somewhat diff erent from the results 
of a study performed during years 1988 – 1996, which enrolled 462 
cirrhotic patients referring to 23 Italian hospitals for liver decom-
pensation ( 23 ). In that study,  ~ 40 % of decompensated cirrhosis 
was attributable to alcohol consumption, whereas a little more than 
half of the subjects were infected by HCV. Th e discrepancy may 
be attributed to diff erent characteristics of the enrolled patients. 
As a matter of fact, in the aforementioned study, all subjects were 
unaware of their condition and received the fi rst diagnosis of 
cirrhosis at the time of decompensation, whereas in our survey 
only one-third of subjects were unaware of their illness before 
decompensation. 
this fi nal multivariable model, AoCLF patients and overt ascites 
patients remained at a signifi cantly higher risk of event compared 
with GEVB patients. 
 Because of the low number of patients belonging to the sub-
groups, overt ascites plus GEVB, HE, portal vein thrombosis, 
and cholangitis categories were not included in the multivariable 
analyses. 
 DISCUSSION 
 Th e present nationwide inception cohort study illustrates the 
epidemiology, clinical features, and disease outcome of patients 
with cirrhosis aft er the onset of their fi rst episode of liver decom-
pensation. Although lack of data from other countries limits the 
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 Figure 2 .  Cumulative incidence of death / OLT and HCC in the overall 
cohort (455 patients). HCC, hepatocellular carcinoma; OLT, orthotopic liver 
transplantation. 
 Table 3 .  Description of observed fi rst clinical events and estimated cumulative incidence of failure by type of decompensation at baseline 
 Category 
 At 
risk 
 Cause of death 
 Total 
deaths  OLT  HCC 
 Cumulative incidence of failure (death and OLT) 
(95 % CI) 
 Hepatic 
failure  Bleeding  Sepsis  HRS  Nonhepatic  1 Year  2 Years  3 Years 
 AoCLF  53  16  4  1  3  2  26  4  2  28 % (16 – 41 % )  53 % (38 – 66 % )  62 % (45 – 75 % ) 
 UD ascites  71  12  1  1  —  1  15  2  4  10 % (4 – 19 % )  18 % (10 – 28 % )  25 % (15 – 36 % ) 
 Overt ascites  230  39  8  5  5  5  65  17  30  17 % (13 – 23 % )  31 % (25 – 37 % )  41 % (33 – 48 % ) 
 GEVB  60  5  4  1  —  1  11  1  8  8 % (3 – 17 % )  12 % (5 – 22 % )  24 % (12 – 38 % ) 
 GEVB  +  overt 
ascites 
 8  —  —  —  —  1  1  0  2  —  16 % (0 – 55 % )  — 
 Other a  33  4  1  1  1  —  7  0  6  20 % (8 – 35 % )  23 % (10 – 40 % )  — 
 AoCLF, acute-on-chronic liver failure; CI, confi dence interval; GEVB, gastroesophageal variceal bleeding; HCC, hepatocellular carcinoma; HRS, hepatorenal syndrome; 
OLT, orthotopic liver transplantation; UD, ultrasonography detected. 
 a Hepatic encephalopathy, portal vein thrombosis, and cholangitis. 
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 In this study, HCV subjects were signifi cantly older than alco-
holics, suggesting that the disease route would be more indolent 
in this population. Additionally, the fi nding that the coexistence 
of HCV and alcohol was associated with the youngest age provides 
solid evidence about the synergistic role of both factors in accelerat-
ing the progression of the disease ( 24 – 27 ). Finally, the observation 
that a relevant proportion of the etiologies of these patients may be 
attributed to NASH confi rms that this disorder is not infrequently 
associated with progression to end-stage liver disease ( 28,29 ). Th e 
reliability of our diagnosis of NASH (still lacking a reliable marker) 
was certifi ed by the fact that the prevalence of diabetes, which is 
strictly linked to the metabolic syndrome, was signifi cantly higher 
in this group of subjects. 
 Th is study fi rst reports prevalence of AoCLF as determinant of 
fi rst decompensation. By using the criteria proposed by APASL 
consensus meeting ( 9 ), which simply included a revisited version of 
the classical Child score, we found that at least 12 % of the episodes 
of fi rst complication in cirrhotic patients could be attributable to 
AoCLF. Th e fact that this information has not been available so far 
is not surprising, as although AoCLF should be always suspected 
in patients with cirrhosis showing sudden liver function deterio-
ration, APASL criteria have not been universally accepted and a 
consensus for the defi nition of this entity has not been reached yet. 
Th is justifi es the lower in-hospital mortality rate (3.4 % vs. 10.4 % ) 
observed in our fi ndings when compared with the one recently 
reported by Katoonizadeh  et al. ( 30 ). Accordingly, despite the fact 
that APASL criteria to defi ne AoCLF were also used in that study, 
the included patients were exclusively aff ected by alcohol-related 
cirrhosis and the proportion of subjects with systemic infl amma-
tory response that emerged to be a main determinant of short-term 
mortality in that study was higher. 
 Th e bigger group of patients with HBV reactivation, concur-
rently with the more severe disease stage of patients at presentation 
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 Figure 3 .  Cumulative incidence of death / OLT by type of decompensation 
at baseline. AoCLF, acute-on-chronic liver failure; GEVB, gastroesophageal 
variceal bleeding; OLT, orthotopic liver transplantation; UD, ultrasonography 
detected.  * Hepatic encephalopathy, portal vein thrombosis, and cholangitis. 
 Table 4 .  Comparison between model considering only MELD score (model 1), model also including type of decompensation (model 2), and 
model also including type of decompensation, age, sex, BMI, ALT, Hb, sodium, and diagnosis of diabetes (model 3) 
  Model 1  Model 2  Model 3 
  HR (95 % CI)  P value  HR (95 % CI)  P value  HR (95 % CI)  P value 
 MELD score (5-point increase)  1.52 (1.31 – 1.76)   <  0.0001  1.37 (1.13 – 1.66)  0.0014  1.32 (1.08 – 1.60)  0.0059 
 AoCLF vs. GEVB    2.35 (1.11 – 4.99)  0.0262  2.50 (1.11 – 5.65)  0.0272 
 Overt ascites vs. GEVB    2.05 (1.11 – 3.77)  0.0214  1.98 (1.02 – 3.84)  0.0452 
 UD vs. GEVB    1.28 (0.61 – 2.68)  0.5166  1.42 (0.63 – 3.17)  0.3985 
 Age (10-year increase)      1.41 (1.22 – 1.64)   <  0.0001 
 Gender (male vs. female)      1.45 (1.00 – 2.12)  0.0501 
 BMI (5-unit increase)      0.80 (0.64 – 1.01)  0.0633 
 ALT (times u.l.n.; 1-unit increase)      1.26 (1.11 – 1.43)  0.0004 
 Hb (g / dl; 1-unit increase)      0.91 (0.83 – 0.99)  0.0306 
 Sodium (mEq / l; 1-unit increase)      0.94 (0.91 – 0.98)  0.0027 
 Diagnosis of diabetes (yes vs. no)      1.63 (1.10 – 2.41)  0.0141 
 Model 2 vs. model 1  LRT 8.7 ( P =0.03)     
 Model 3 vs. model 2  LRT 58.5 ( P  <  0.0001)     
 ALT, alanine transaminase; AoCLF, acute-on-chronic liver failure; BMI, body mass index; CI, confi dence interval; GEVB, gastroesophageal variceal bleeding; Hb, hemo-
globin; HR, hazard ratio; LRT, likelihood ratio test; MELD, Model for End-Stage Liver Disease; UD, ultrasonography detected; u.l.n., upper limit of normal. 
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and / or endoscopic variceal ligation, (ii) use of prophylactic anti-
biotic and vasoactive therapy, (iii) a collection of prospective 
cases instead of retrospective cohorts ( 9 ), (iv) exclusive inclusion 
of patients at their fi rst decompensation in spite of the presence 
of patients with previous decompensation, and (v) inclusion of 
patients with concurrent GEVB and ascites in the same subgroup, 
whereas in our study patients were considered separately. 
 We acknowledge that the results of this survey require an exter-
nal validation, possibly performed in countries where the preva-
lence of some risk factors of cirrhosis is diff erent. We also admit 
that the  post hoc allocation of patients with AoCLF, as well as 
the negligible number of patients with multiorgan failure in this 
subgroup of subjects, may impair the strength of our study. 
 In conclusion, according to the APASL criteria, a substantial 
proportion of fi rst decompensation in patients with cirrhosis in 
Italy may be attributable to AoCLF, a distinct syndrome that, irre-
spective of short-term outcome, had a very poor prognosis over 
a 3-year follow-up period. In addition, as the risk of mortality of 
patients who developed UD ascites was not negligible, subjects 
who developed this complication require a careful follow-up. Both 
prevalence and mortality rates of GEVB were extremely lower 
in comparison with those previously described in past surveys. 
Although the underlying liver functional status, as certifi ed by 
MELD score, gives reason for diverse rates of mortality between 
the above-mentioned categories, other characteristics of patients, 
such as older age, sex male, obesity, and presence of diabetes across 
diff erent types of fi rst decompensation, were independently asso-
ciated with the 3-year mortality risk in the single individual. 
 Both practicing specialists and general practitioners may use 
these results to (i) better categorize the population of cirrhotic 
patients at the time of their fi rst complication, (ii) identify the sub-
jects with worst prognosis at more urgent need for liver transplant, 
and (iii) standardize the criteria for including patients in future 
studies. Health-care systems may utilize these data to update 
the knowledge of the impact of this disease and to estimate the 
amount of economic investments that will be required to aff ord 
this condition. 
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(median MELD 29 vs. 20, high proportion of both HRS and mul-
tiorgan failure), may justify the diff erent rates (63 % vs. 25 % ) of 
3-month mortality between our survey and another study car-
ried out by Garg  et al. ( 31 )on 91 patients with APASL-AoCLF. In 
addition, the low number of multiorgan failure in our study also 
explains the lack of diff erence observed in in-hospital mortality 
between AoCLF and decompensated cirrhosis. Regarding this, 
whether patients with other multiple end-organ failures (as allowed 
by the EASL-Chronic Liver Failure (CLIF) Consortium Canonic 
study) should be included in AoCLF defi nition is still a matter of 
debate ( 32 ). Nevertheless, while waiting for the attainment of a 
general agreement, these criteria might be useful if applied in daily 
practice, as the main innovation that has emerged from our study 
is that the adoption of APASL criteria for AoCLF enables to infer 
a prospect of the long-term prognosis at the time of the patient ’ s 
fi rst complication. 
 Aft er exclusion of patients with AoCLF, ascites still remained 
the most frequent complication, and in a not-negligible number 
of cases it could be identifi ed only by ultrasound examination . 
To our knowledge, no study has compared the survival rate of 
patients with UD ascites with that of patients with overt ascites 
so far. Regrettably, we did not compare a reference population 
of patients with compensated cirrhosis but we observed that the 
3-year mortality rate of patients with UD ascites was approximately 
eightfold higher than the one reported by other previous investiga-
tions in patients with compensated disease ( 33,34 ). Th is fi nding, 
in addition to the rapid progression of overt ascites in approxi-
mately one-fi ft h of cases, is relevant from a clinical point of view 
and consistent with the assumption that UD ascites represents a 
very early stage of liver decompensation. Meanwhile, whether the 
practice of a salt-restricted diet and the expanding use of diuretics /
 albumin could be benefi cial in these patients are matters of 
dedicated studies. 
 Survival rates in patients with overt ascites paralleled those 
reported by Planas  et al. ( 35 ) in HCV patients and those described 
by Alvarez  et al. ( 36 )in alcohol-related cirrhosis. Th e lack of 
improvement of standard treatments of ascites over the past years, 
as well as the rapid transition to more severe conditions (refractory 
ascites, GEVB, SBP, and HRS), indicates that this complication, 
more accurately than bleeding, refl ects a severe impairment of 
both circulatory and renal function, giving the justifi cation of the 
concordance of our results with those obtained in the past ( 37 ). 
 Although the prevalence of subjects with concurrent SBP was 
low, this group of patients showed a signifi cantly lower probabil-
ity to survive over the fi rst 6 months of follow-up, compared with 
those with ascites and no SBP. Th e fi nding that the vast majority of 
these cases received antibiotic prophylaxis according to interna-
tional recommendations ( 38 ) indicates that the epidemiology of 
bacterial infections has changed over the years and that the level of 
effi  cacy of the available therapy schedule has lowered ( 39,40 ). 
 In comparison with previous estimates reported by D ’Amico 
 et al. ( 9 ), we found that both prevalence of GEVB as a fi rst cause of 
decompensation and mortality rates of patients who have bled were 
extremely low. Th is discrepancy can be ascribed to several reasons: 
(i) current widespread use of primary prophylaxis with  β -blockers 
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 Study Highlights 
 WHAT IS CURRENT KNOWLEDGE 
 3 During the disease course of liver cirrhosis, increasing 
portal pressure and decreasing liver function cause the 
development of hepatic decompensation. 
 3 This clinical event marks a crucial turning point as it is 
associated with a higher risk of further complications and 
liver-related death. 
 3 Predictive models of mortality based on clinical features of 
liver decompensation are widely accepted in daily practice. 
 3 However, the above-mentioned estimates have been 
developed by a systematic review of literature that includes 
studies carried out when treatment of portal hypertension-
related complications were still in its infancy and new 
emerging conditions such as acute-on-chronic liver failure 
(AoCLF) were not assessed. 
 WHAT IS NEW HERE 
 3 AoCLF accounted for a relevant proportion of fi rst decom-
pensation in cirrhotic patients, the occurrence of which 
was associated with the poorest 3-year survival rate. 
 3 On the basis of their not-negligible mortality rate, patients 
who develop ultrasound-detected (UD) ascites require 
clinical surveillance analogous to the one required by 
patients with overt ascites. 
 3 In patients affected by gastroesophageal variceal bleeding 
(GEVB), the mortality rate was particularly lower in 
comparison with those previously reported. 
 3 In the single individual affected by cirrhosis of any etiology, 
at the time of the onset of fi rst episode of decompensation, 
a more accurate prognosis of 3-year mortality is enabled by 
combining multiple risk factors like type of complication, 
older age, male gender, obesity, diabetes, and Model for 
End-Stage Liver Disease (MELD) score. 
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 APPENDIX 
 AISF – EPA-SCO Collaborative Study Group: Angera: A. Balzarini and D. Sala; Bergamo: G. Colloredo and M. Sonzogni; 
Bologna: F. Conti and A. Marri; Bolzano: M. Felder and A. Mega; Ciri é : E. Vecchi; Como: A.E. Colombo; Ferrara: S. Boccia and 
L. Simone; Marino: L. Bellis; Melegnano: G. Vitaliani; Milano Fatebenefratelli: S. Bruno, A. Camera, and S. Saibeni; Milano Niguarda: 
C. Prisco and M. Vinci; Milano Ospedale Maggiore: M.L. Fracanzani; Milano Modena: C. Vandelli; Napoli Policlinico: M. Svelto; 
Napoli Centro Epatiti Virali: G.B. Gaeta; Napoli II Universit à : G. Cotticelli; Napoli Federico II: D. Amoruso, N; Napoli DAS Malattie 
Infettive SUN: M. Stanzione; Napoli Cardarelli: M. De Luca; Palermo: P.L. Almasio, M. D ’ Amico, F.D ’ Angelo; C. Cottone; Roma La 
Sapienza: C. Furlan and G. Taliani; Roma Gemelli: B.E. Annichiarico, G. Di Gioacchino, A. Gasbarrini, and M. Santoro; Rozzano: 
M. Tommasini; San Donato Milanese: G. Gobbo and F. Salerno; San Giovanni Rotondo: D. Gioff reda and G.A. Niro. 
